Skip to content
On this page:OverviewPublicationsResearchersInstitutionsOpen access
PICO Portalanswers from OpenAlex

Ovid Therapeutics (United States)

InstitutionResearch output, impact & collaborations

Ovid Therapeutics (United States) is a institution indexed in PICO Portal from OpenAlex.

What is known about Ovid Therapeutics (United States)?

PICO Portalrecord summary

Ovid Therapeutics (United States) is a research organisation in New York, United States. OpenAlex records 99 works and 2,280 citations for it. 1 researchers list it as their most recent affiliation.

How many works does Ovid Therapeutics (United States) have?

PICO Portalindexed works

Ovid Therapeutics (United States) has 99 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Ovid Therapeutics (United States) have?

PICO Portalcitation count

Ovid Therapeutics (United States) has 2,280 citations in the OpenAlex counts PICO Portal stores.

How many researchers are at Ovid Therapeutics (United States)?

PICO Portalresearcher count

Ovid Therapeutics (United States) has 1 researchers in the PICO Portal index.

What is the average h-index at Ovid Therapeutics (United States)?

PICO Portalavg h-index

Ovid Therapeutics (United States) has an average h-index of 74 in OpenAlex.

What is the ROR of Ovid Therapeutics (United States)?

PICO Portalror

The ROR for Ovid Therapeutics (United States) is on the source record.

What is the OpenAlex record for Ovid Therapeutics (United States)?

PICO Portalopenalex

The OpenAlex for Ovid Therapeutics (United States) is on the source record.

Who are the most-cited researchers behind Ovid Therapeutics (United States)?

PICO Portaltop researchers by citations
1
Matthew J. During · Neuroscience and Neuropharmacology Research
217 works21,591 citations

What are the most-cited papers on Ovid Therapeutics (United States)?

PICO Portalmost cited works
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial
Michael G. Kaplitt, Andrew Feigin, Chengke Tang, Helen L. Fitzsimons, Paul J. Mattis, P. Lawlor, Ross Bland, Deborah Young, Kristin Strybing, David Eidelberg, Matthew J. During
The Lancet. 20071,072 Citations
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
Peter A. LeWitt, Ali R. Rezai, Maureen A. Leehey, Steven Ojemann, Alice W. Flaherty, Emad N. Eskandar, Sandra K. Kostyk, Karen Thomas, Atom Sarkar, Mustafa Siddiqui, Stephen B. Tatter, Jason M. Schwalb, Kathleen L. Poston, Jaimie M. Henderson, Roger Kurlan, Irene Hegeman Richard, Lori Van Meter, Christine V. Sapan, Matthew J. During, Michael G. Kaplitt, Andrew Feigin
The Lancet Neurology. 2011675 Citations

How much of the research on Ovid Therapeutics (United States) is open access?

PICO Portalopen access share
0%OPEN ACCESS
Gold
0%
Green
0%
Hybrid
0%
Bronze
0%
Closed
100%
470M+ articles · 14-day free trial